Long-term outcome in patients with aneurysmal subarachnoid hemorrhage requiring mechanical ventilation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 15 08 2020
accepted: 16 02 2021
entrez: 12 3 2021
pubmed: 13 3 2021
medline: 13 10 2021
Statut: epublish

Résumé

Patients affected with aneurysmal subarachnoid hemorrhage (aSAH) often require intensive care, and then present distinctive outcome from less severe patients. We aimed to specify their long-term outcome and to identify factors associated with poor outcome. We conducted a retrospective study in a French university hospital intensive care unit. Patients with aSAH requiring mechanical ventilation hospitalized between 2010 and 2015 were included. At least one year after initial bleeding, survival and degree of disability were assessed using the modified Rankin Scale (mRS) via telephone interviews. A multivariable logistic regression analysis was performed to determine independent factors associated with poor outcome defined as mRS≥3. Two-hundred thirty-six patients were included. Among them, 7 were lost to follow-up, and 229 were analyzed: 73 patients (32%) had a good outcome (mRS<3), and 156 (68%) had a poor outcome (mRS≥3). The estimated 1-year survival rate was 63%. One-hundred sixty-three patients patients (71%) suffered from early brain injuries (EBI), 33 (14%) from rebleeding, 80 (35%) from vasospasm and 63 (27%) from delayed cerebral ischemia (DCI). Multivariable logistic regression identified independent factors associated with poor outcome including delay between aSAH diagnosis and mRS assessment (OR, 0.96; 95% CI, 0.95-0.98; p<.0001), age (OR per 10 points, 1.57; 95% CI, 1.12-2.19; p = 0.008), WFNS V versus WFNS III (OR, 5.71; 95% CI 1.51-21.61; p = 0.004), subarachnoid rebleeding (OR, 6.47; 95% CI 1.16-36.06; p = 0.033), EBI (OR, 4.52; 95% CI 1.81-11.29; p = 0.001) and DCI (OR, 4.73; 95% CI, 1.66-13.49; p = 0.004). Among aSAH patients requiring assisted ventilation, two-third of them survived at one year, and one-third showed good long-term outcome. As it appears as an independant factor associated with poor outcome, DCI shoud retain particular attention in future studies beyond angiographic vasospasm.

Sections du résumé

BACKGROUND
Patients affected with aneurysmal subarachnoid hemorrhage (aSAH) often require intensive care, and then present distinctive outcome from less severe patients. We aimed to specify their long-term outcome and to identify factors associated with poor outcome.
METHODS
We conducted a retrospective study in a French university hospital intensive care unit. Patients with aSAH requiring mechanical ventilation hospitalized between 2010 and 2015 were included. At least one year after initial bleeding, survival and degree of disability were assessed using the modified Rankin Scale (mRS) via telephone interviews. A multivariable logistic regression analysis was performed to determine independent factors associated with poor outcome defined as mRS≥3.
RESULTS
Two-hundred thirty-six patients were included. Among them, 7 were lost to follow-up, and 229 were analyzed: 73 patients (32%) had a good outcome (mRS<3), and 156 (68%) had a poor outcome (mRS≥3). The estimated 1-year survival rate was 63%. One-hundred sixty-three patients patients (71%) suffered from early brain injuries (EBI), 33 (14%) from rebleeding, 80 (35%) from vasospasm and 63 (27%) from delayed cerebral ischemia (DCI). Multivariable logistic regression identified independent factors associated with poor outcome including delay between aSAH diagnosis and mRS assessment (OR, 0.96; 95% CI, 0.95-0.98; p<.0001), age (OR per 10 points, 1.57; 95% CI, 1.12-2.19; p = 0.008), WFNS V versus WFNS III (OR, 5.71; 95% CI 1.51-21.61; p = 0.004), subarachnoid rebleeding (OR, 6.47; 95% CI 1.16-36.06; p = 0.033), EBI (OR, 4.52; 95% CI 1.81-11.29; p = 0.001) and DCI (OR, 4.73; 95% CI, 1.66-13.49; p = 0.004).
CONCLUSION
Among aSAH patients requiring assisted ventilation, two-third of them survived at one year, and one-third showed good long-term outcome. As it appears as an independant factor associated with poor outcome, DCI shoud retain particular attention in future studies beyond angiographic vasospasm.

Identifiants

pubmed: 33711023
doi: 10.1371/journal.pone.0247942
pii: PONE-D-20-25453
pmc: PMC7954305
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0247942

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Rev Neurol. 2014 Jan;10(1):44-58
pubmed: 24323051
Crit Care. 2016 Jan 23;20:21
pubmed: 26801901
Anaesth Crit Care Pain Med. 2018 Dec;37(6):607-614
pubmed: 30580775
Lancet Neurol. 2009 Jul;8(7):635-42
pubmed: 19501022
Br J Anaesth. 2012 Sep;109(3):315-29
pubmed: 22879655
N Engl J Med. 2006 Jan 26;354(4):387-96
pubmed: 16436770
Neurosurg Clin N Am. 2005 Jul;16(3):501-16, vi
pubmed: 15990041
Stroke. 2011 Aug;42(8):2276-9
pubmed: 21680905
Stroke. 2010 Oct;41(10):2391-5
pubmed: 20798370
Stroke. 2015 Oct;46(10):3014-9
pubmed: 26152299
Stroke. 2016 Dec;47(12):2945-2951
pubmed: 27827324
Stroke. 2009 Jun;40(6):1963-8
pubmed: 19359629
World Neurosurg. 2018 Jul;115:e292-e298
pubmed: 29660554
Scott Med J. 1957 May;2(5):200-15
pubmed: 13432835
Acta Neurochir Suppl (Wien). 1988;42:81-4
pubmed: 3055838
Neurocrit Care. 2012 Jun;16(3):354-62
pubmed: 22528278
Neurocrit Care. 2007;7(1):10-7
pubmed: 17657652
Stroke. 2012 Jun;43(6):1711-37
pubmed: 22556195
J Clin Neurosci. 2016 Nov;33:142-147
pubmed: 27450281
J Cardiovasc Echogr. 2016 Apr-Jun;26(2):28-41
pubmed: 28465958
Stroke. 2010 Aug;41(8):e519-36
pubmed: 20595669
Neurocrit Care. 2009;11(2):165-71
pubmed: 18202923
Stroke. 2017 Nov;48(11):2958-2963
pubmed: 28974630
J Cereb Blood Flow Metab. 2006 Nov;26(11):1341-53
pubmed: 16482081
Stroke. 2008 Mar;39(3):893-8
pubmed: 18239182
J Cereb Blood Flow Metab. 2012 Mar;32(3):447-55
pubmed: 22146194
Anaesth Crit Care Pain Med. 2019 Jun;38(3):251-257
pubmed: 31079704
Neurosurgery. 2017 Jun 1;80(6):967-974
pubmed: 28327912
Neurocrit Care. 2016 Dec;25(3):338-350
pubmed: 27651379
Stroke. 1997 Mar;28(3):660-4
pubmed: 9056628
Crit Care Med. 2017 Feb;45(2):e138-e145
pubmed: 27749342
Lancet Neurol. 2009 May;8(5):427-33
pubmed: 19329361
J Cereb Blood Flow Metab. 2013 Dec;33(12):1825-37
pubmed: 24064495
Neuroradiol J. 2016 Feb;29(1):72-81
pubmed: 26825134

Auteurs

Kevin Chalard (K)

Department of Critical Care Medicine and Anesthesiology (DAR C), Gui de Chauliac University Hospital of Montpellier, Montpellier, France.
IGF, Univ. Montpellier, CNRS, Inserm, Montpellier, France.

Vivien Szabo (V)

Department of Critical Care Medicine and Anesthesiology (DAR C), Gui de Chauliac University Hospital of Montpellier, Montpellier, France.
IGF, Univ. Montpellier, CNRS, Inserm, Montpellier, France.

Frederique Pavillard (F)

Department of Critical Care Medicine and Anesthesiology (DAR C), Gui de Chauliac University Hospital of Montpellier, Montpellier, France.

Flora Djanikian (F)

Department of Critical Care Medicine and Anesthesiology (DAR C), Gui de Chauliac University Hospital of Montpellier, Montpellier, France.

Cyril Dargazanli (C)

Department of Neuroradiology, Gui de Chauliac University Hospital of Montpellier, Montpellier, France.

Nicolas Molinari (N)

IMAG, CNRS, Univ Montpellier, CHU Montpellier, Montpellier, France.

Federico Manna (F)

Epidemiology and Clinical Research Department, University Hospital of Montpellier, Montpellier, France.

Vincent Costalat (V)

Department of Neuroradiology, Gui de Chauliac University Hospital of Montpellier, Montpellier, France.

Gerald Chanques (G)

Department of Critical Care Medicine and Anesthesiology (DAR B), Saint Eloi University Hospital of Montpellier and PhyMedExp, University of Montpellier, INSERM, CNRS, Montpellier, France.

Pierre-Francois Perrigault (PF)

Department of Critical Care Medicine and Anesthesiology (DAR C), Gui de Chauliac University Hospital of Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH